Details for New Drug Application (NDA): 205570
✉ Email this page to a colleague
NDA 205570 describes ARGATROBAN IN SODIUM CHLORIDE, which is a drug marketed by Cipla, Gland Pharma Ltd, Sandoz, Accord Hlthcare, and Eugia Pharma Speclts, and is included in five NDAs. It is available from three suppliers. There are two patents protecting this drug. Additional details are available on the ARGATROBAN IN SODIUM CHLORIDE profile page.
The generic ingredient in ARGATROBAN IN SODIUM CHLORIDE is argatroban. There are eleven drug master file entries for this compound. Eleven suppliers are listed for this compound. Additional details are available on the argatroban profile page.
The generic ingredient in ARGATROBAN IN SODIUM CHLORIDE is argatroban. There are eleven drug master file entries for this compound. Eleven suppliers are listed for this compound. Additional details are available on the argatroban profile page.
Summary for 205570
| Tradename: | ARGATROBAN IN SODIUM CHLORIDE |
| Applicant: | Gland Pharma Ltd |
| Ingredient: | argatroban |
| Patents: | 0 |
Pharmacology for NDA: 205570
| Mechanism of Action | Thrombin Inhibitors |
Suppliers and Packaging for NDA: 205570
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| ARGATROBAN IN SODIUM CHLORIDE | argatroban | INJECTABLE;INTRAVENOUS | 205570 | ANDA | Gland Pharma Limited | 68083-141 | 68083-141-02 | 2 VIAL in 1 CARTON (68083-141-02) / 125 mL in 1 VIAL (68083-141-01) |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | INJECTABLE;INTRAVENOUS | Strength | 125MG/125ML (1MG/ML) | ||||
| Approval Date: | May 22, 2017 | TE: | AP | RLD: | No | ||||
Complete Access Available with Subscription
